Dendritic Cell-Based Immunotherapy: State of the Art and Beyond
Dendritic Cell-Based Immunotherapy: State of the Art and Beyond
复制标题
DOI：
10.1158/1078-0432.ccr-15-1399
复制
发表时间：
2016-04-15
影响因子：
11.5
通讯作者：
Figdor, Carl G.
中科院分区：
文献类型：
--
作者：
Bol, Kalijn F.;Schreibelt, Gerty;Figdor, Carl G.
癌症患者的树突状细胞（DC）疫苗旨在诱导或增强针对肿瘤抗原的有效抗肿瘤免疫反应，并在1990年代的一项临床试验中首次探讨。超过二十年后，已经进行了许多临床试验或正在进行各种DC子集，培养方案和治疗方案。 DC疫苗接种的安全及其诱导抗肿瘤反应的能力已经明确建立了；但是，尽管报告了长期益处的分散患者，但直流疫苗尚未履行其承诺，这可能主要是由于缺乏大规模良好的II/III期试验。为了允许有意义的多中心III期试验，应在中心之间进行标准化直流疫苗的生产，这现在正变得可行。为了提高基于DC的免疫疗法的功效，可以将其与其他疗法结合使用。 （c）2016 AACR。
Dendritic cell (DC) vaccination in cancer patients aims to induce or augment an effective antitumor immune response against tumor antigens and was first explored in a clinical trial in the 1990s. More than two decades later, numerous clinical trials have been performed or are ongoing with a wide variety of DC subsets, culture protocols, and treatment regimens. The safety of DC vaccination and its ability to induce antitumor responses have clearly been established; however, although scattered patients with long-term benefit were reported, DC vaccines have not yet fulfilled their promise, perhaps mainly due to the lack of large-scale well-conducted phase II/III trials. To allow meaningful multicenter phase III trials, the production of DC vaccines should be standardized between centers which is now becoming feasible. To improve the efficacy of DC-based immunotherapy, it could be combined with other treatments. (C) 2016 AACR.